Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A strategy for developing effective amyotropic lateral sclerosis pharmacotherapy: from clinical trials to novel pharmacotherapeutic strategies.

Expert opinion on pharmacotherapy - 1 Aug 2008

Yamamoto Masahiko, Tanaka Fumiaki, Tatsumi Hiroshi, Sobue Gen

Abstract excerpt

BACKGROUND: The pathomechanism of sporadic amyotropic lateral sclerosis is not clearly understood, although a proportion of familial amyotropic lateral sclerosis is caused by superoxide dismutase 1 mutations. Theories based on studies of human post-mortem tissue, research on animal models and in vitro work have been proposed for the pathogenesis of amyotropic lateral sclerosis, but the pathogenesis is not the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Gene Expression Profiling

Share to Genetic Therapy

Share to Stem Cell Transplantation

Share to Superoxide Dismutase

Share to Superoxide Dismutase-1

Source

Identifiers

PMID: 18627324
DOI: 10.1517/14656566.9.11.1845

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A strategy for developing effective amyotropic lateral sclerosis pharmacotherapy: from clinical trials to novel pharmacotherapeutic strategies.PMID 18627324Read ↗

Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis.Semantic proximity Read ↗

Diagnosis, pathogenesis and therapeutic targets in amyotrophic lateral sclerosis.Semantic proximity Read ↗

Amyotrophic lateral sclerosis (motor neuron disease): proposed mechanisms and pathways to treatment.Semantic proximity Read ↗

Therapeutic advances in amyotrophic lateral sclerosis.Semantic proximity Read ↗

An update on superoxide dismutase 1 in familial amyotrophic lateral sclerosis.Semantic proximity Read ↗

[Familial Amyotrophic Lateral Sclerosis].Semantic proximity Read ↗

Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications.Semantic proximity Read ↗

Treatment of hereditary amyotrophic lateral sclerosis.Semantic proximity Read ↗

Current developments in gene therapy for amyotrophic lateral sclerosisSemantic proximity Read ↗

Treatment of amyotrophic lateral sclerosis--what is the next step?Semantic proximity Read ↗

Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studiesSemantic proximity Read ↗

Mechanisms, models and biomarkers in amyotrophic lateral sclerosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.